{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:13:24Z","timestamp":1790856804389,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.autrev.2022.103206","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T03:08:14Z","timestamp":1664766494000},"page":"103206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["COVID-19 and the antiphospholipid syndrome"],"prefix":"10.1016","volume":"21","author":[{"given":"Manuel","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103206_bb0005","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103206_bb0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2022.103206_bb0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China Lancet"},{"key":"10.1016\/j.autrev.2022.103206_bb0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan","volume":"46","author":"Ruan","year":"2020","journal-title":"China Intens Care Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154886","article-title":"The intersection of COVID-19 and autoimmunity","volume":"131","author":"Knight","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103206_bb0040","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2019-215361","article-title":"Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals","volume":"78","author":"Jog","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0045","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.27408","article-title":"Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells","volume":"62","author":"Quan","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103206_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/eji.201242552","article-title":"EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape","volume":"43","author":"Severa","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0055","article-title":"Epstein Barr virus and autoimmune responses in systemic lupus erythematosus","volume":"11","author":"Jog","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.624483","article-title":"T-helper cell subset response is a determining factor in COVID-19 progression","volume":"11","author":"Gil-Etayo","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.autrev.2022.103206_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020296","article-title":"An early Th1 response is a key factor for a favorable COVID-19 evolution","volume":"10","author":"Gil-Etayo","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2022.103206_bb0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0075","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S2665-9913(21)00078-3","article-title":"Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?","volume":"3","author":"Mehta","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0080","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk","volume":"56","author":"Mehta","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103206_bb0085","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A decade of JAK inhibitors: What have we learned and what may be the future?","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102592","article-title":"The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - a systematic review of the literature","volume":"117","author":"Novelli","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103206_bb0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01618-2020","article-title":"Similarities between COVID-19 and anti-MDA5 syndrome: What can we learn for better care?","volume":"56","author":"Giannini","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103206_bb0100","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1136\/annrheumdis-2020-218594","article-title":"Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future","author":"Wang","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0105","article-title":"Transient monoarthritis and psoriatic skin lesions following COVID-19","author":"De Stefano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/RHU.0000000000001560","article-title":"A case of reactive arthritis secondary to coronavirus disease 2019 infection","volume":"26","author":"Liew","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0115","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1093\/rheumatology\/keaa691","article-title":"A case of psoriatic arthritis triggered by SARS-CoV-2 infection","volume":"60","author":"Novelli","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103206_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108166","article-title":"Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus","volume":"164","author":"Chee","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.autrev.2022.103206_bb0125","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1016\/S2665-9913(20)30216-2","article-title":"Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection","volume":"2","author":"Talarico","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218315","article-title":"Comparative analysis of synovial inflammation after SARS-CoV-2 infection","volume":"80","author":"Alivernini","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103206_bb0140","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.autrev.2022.103206_bb0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2020.06.029","article-title":"The hypercoagulable state in COVID-19: incidence, pathophysiology, and management","volume":"194","author":"Abou-Ismail","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0150","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2666-5247(20)30115-4","article-title":"Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study","volume":"1","author":"Hanley","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.autrev.2022.103206_bb0155","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis","volume":"29","author":"Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2022.103206_bb0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.857573","article-title":"Laboratory biomarkers for diagnosis and prognosis in COVID-19","volume":"13","author":"Battaglini","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0170","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.120.049465","article-title":"Unexpected features of cardiac pathology in COVID-19 infection","volume":"142","author":"Fox","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2022.103206_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.autrev.2022.103206_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2018-04-841585","article-title":"Hypoxia downregulates protein S expression","volume":"132","author":"Pilli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103206_bb0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcrc.2017.09.035","article-title":"Increased DNA damage and increased apoptosis and necrosis in patients with severe sepsis and septic shock","volume":"43","author":"Bahar","year":"2018","journal-title":"J Crit Care"},{"key":"10.1016\/j.autrev.2022.103206_bb0195","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic vascular endothelial cells become procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103206_bb0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-019-0205-9","article-title":"Hypoxia and HIF activation as a possible link between sepsis and thrombosis","volume":"17","author":"Evans","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.autrev.2022.103206_bb0205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.200606027","article-title":"Novel cell death program leads to neutrophil extracellular traps","volume":"176","author":"Fuchs","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2022.103206_bb0210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fimmu.2016.00366","article-title":"Neutrophil extracellular traps go viral","volume":"7","author":"Schonrich","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103206_bb0220","article-title":"NETosis and neutrophil extracellular traps in COVID-19: Immunothrombosis and beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0225","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103206_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"issue":"1","key":"10.1016\/j.autrev.2022.103206_bb0235","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-022-01133-5","article-title":"Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation.","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2022.103206_bb0240","volume":"6","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0245","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol Rep"},{"key":"10.1016\/j.autrev.2022.103206_bb0250","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2022.103206_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584241","article-title":"Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome","volume":"11","author":"Borghi","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103206_bb0260","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/joim.13123","article-title":"Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications","volume":"288","author":"Mendoza-Pinto","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0265","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103206_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103206_bb0275","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102094","article-title":"Anti-phosphatidylserine\/prothrombin antibodies in healthy women with unexplained recurrent pregnancy loss","volume":"10","author":"Pleguezuelo","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0285","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2019.00376","article-title":"Reliability of lupus anticoagulant and anti-phosphatidylserine\/prothrombin autoantibodies in antiphospholipid syndrome: a multicenter study","volume":"10","author":"Sciascia","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0290","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103206_bb0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2019.11.029","article-title":"Anti-beta2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome","volume":"185","author":"Liu","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.autrev.2012.08.002","article-title":"The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review","volume":"12","author":"Meijide","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103206_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21238972","article-title":"The weight of IgA anti-beta2glycoprotein I in the antiphospholipid syndrome pathogenesis: closing the gap of seronegative antiphospholipid syndrome","volume":"21","author":"Cabrera-Marante","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103206_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.665741","article-title":"Presence of extra-criteria antiphospholipid antibodies is an independent risk factor for ischemic stroke","volume":"8","author":"Naranjo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0315","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2017.05.016","article-title":"Early mortality after heart transplantation related to IgA anti-beta2-glycoprotein I antibodies","volume":"36","author":"Delgado","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.autrev.2022.103206_bb0320","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/TP.0000000000001199","article-title":"The presence of pretransplant antiphospholipid antibodies IgA anti-beta-2-glycoprotein I as a predictor of graft thrombosis after renal transplantation","volume":"101","author":"Morales","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2022.103206_bb0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant)","volume":"20","author":"Mendoza-Pinto","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2022.103206_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1023\/B:JOCI.0000018058.28764.ce","article-title":"Antiphospholipid syndrome infectious origin","volume":"24","author":"Blank","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0335","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103206_bb0340","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0345","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with COVID-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-021-01029-3","article-title":"Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?","volume":"23","author":"Foret","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2022.103206_bb0355","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-020-02335-w","article-title":"Lupus anticoagulant and mortality in patients hospitalized for COVID-19","volume":"52","author":"Gazzaruso","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.autrev.2022.103206_bb0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.10.017","article-title":"Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients","volume":"208","author":"Constans","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00296-021-04875-7","article-title":"Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study","volume":"41","author":"Najim","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103206_bb0370","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0375","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/joim.13126","article-title":"High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?","volume":"289","author":"Pineton de Chambrun","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2020.07.016","article-title":"Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?","volume":"195","author":"Siguret","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0385","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0390","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/annrheumdis-2021-220206","article-title":"Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients","volume":"80","author":"Trahtemberg","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0395","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2020.05.017","article-title":"Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism","volume":"192","author":"Galeano-Valle","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0400","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/cts.12908","article-title":"COVID-19 and immunological dysregulation: can autoantibodies be useful?","volume":"14","author":"Pascolini","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2022.103206_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218100","article-title":"Presence of antiphospholipid antibodies in COVID-19: a case series study","volume":"80","author":"Amezcua-Guerra","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102822","article-title":"Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent","volume":"20","author":"Vollmer","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103206_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.911979","article-title":"Persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with SARS-CoV-2 infection","volume":"13","author":"Espinosa","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080899","article-title":"Anti-phospholipid antibodies and COVID-19 thrombosis: a co-star, not a supporting actor","volume":"9","author":"Gil-Etayo","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2022.103206_bb0425","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211042115","article-title":"A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients","volume":"35","author":"Gasparini","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.autrev.2022.103206_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102729","article-title":"Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward","volume":"20","author":"Le Joncour","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103206_bb0435","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/art.41634","article-title":"Antiphospholipid autoantibodies and thrombosis in patients with COVID-19: comment on the article by Bertin et al","volume":"73","author":"Frapard","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0440","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.41425","article-title":"Antiphospholipid antibodies in critically ill patients with COVID-19","volume":"72","author":"Xiao","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103206_bb0445","doi-asserted-by":"crossref","first-page":"e2869","DOI":"10.1093\/cid\/ciaa1496","article-title":"Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies","volume":"73","author":"Hasan Ali","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0450","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10067-021-05580-3","article-title":"Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies","volume":"40","author":"Cristiano","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0455","article-title":"Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19)","volume":"3","author":"Lerma","year":"2020","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2022.103206_bb0460","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr2.11245","article-title":"Beta-2-glycoprotein-I deficiency could precipitate an antiphospholipid syndrome-like Prothrombotic situation in patients with coronavirus disease 2019","volume":"3","author":"Serrano","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0465","first-page":"754","article-title":"Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases","volume":"38","author":"Gatto","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0470","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.41777","article-title":"Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality","volume":"73","author":"Gendron","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0475","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12543","article-title":"Evaluation of three fully automated immunoassay systems for detection of IgA anti-beta 2-glycoprotein I antibodies","volume":"38","author":"Perez","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2022.103206_bb0480","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.41409","article-title":"Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity","volume":"72","author":"Bertin","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0485","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s10067-020-05180-7","article-title":"High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia","volume":"39","author":"Gazzaruso","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0490","article-title":"Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19","volume":"4","author":"Anaya","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2022.103206_bb0495","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2022.103206_bb0500","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3389\/fneur.2020.00806","article-title":"Neurological manifestations in critically ill patients with COVID-19: a retrospective study","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2022.103206_bb0505","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17539","article-title":"Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19)","volume":"3","author":"Reyes Gil","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2022.103206_bb0510","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/annrheumdis-2020-218009","article-title":"Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19","volume":"79","author":"Vlachoyiannopoulos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103206_bb0515","first-page":"437","article-title":"Assessment of antiphospholipid antibodies during the follow-up of patients after SARS-CoV-2 infection","volume":"158","author":"Rosales-Castillo","year":"2022","journal-title":"Med Clin (Engl Ed)"},{"key":"10.1016\/j.autrev.2022.103206_bb0520","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/jth.14994","article-title":"Antiphospholipid antibodies in patients with COVID-19: a relevant observation?","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103206_bb0525","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3855\/jidc.15423","article-title":"The clinical significance of antiphospholipid antibodies in COVID-19 infection","volume":"16","author":"Atalar","year":"2022","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.autrev.2022.103206_bb0530","first-page":"e280","article-title":"Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19)","volume":"42","author":"Lopez","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2022.103206_bb0535","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2020.06.042","article-title":"The pathogenesis of thromboembolic disease in covid-19 patients: could be a catastrophic antiphospholipid syndrome?","volume":"194","author":"Previtali","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0540","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017773","article-title":"High prevalence of acquired thrombophilia without prognosis value in patients with coronavirus disease 2019","volume":"9","author":"Ferrari","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.autrev.2022.103206_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687534","article-title":"Antiphospholipid antibodies and infection: non Nova Sed Nove","volume":"12","author":"Sciascia","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103206_bb0550","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/ijlh.13334","article-title":"Lupus anticoagulant in patients with COVID-19","volume":"43","author":"Tvito","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2022.103206_bb0555","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2012.05.006","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome","volume":"12","author":"Mahler","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103206_bb0560","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14397595.2021.1892257","article-title":"Antiphospholipid antibodies in COVID-19-associated pneumonia patients in intensive care unit","volume":"32","author":"Karahan","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0565","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2019.02.008","article-title":"High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50years using the standardized protocol for thrombophilia screening","volume":"176","author":"Goldman-Mazur","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2022.103206_bb0570","first-page":"623","article-title":"The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies","volume":"16","author":"Fields","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103206_bb0575","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.revmed.2008.05.020","article-title":"Antiphospholipid antibodies, antiphospholipid syndrome and viral infections","volume":"30","author":"Sene","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2022.103206_bb0580","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0037-1614978","article-title":"IgA anticardiolipin antibodies--relation with other antiphospholipid antibodies and clinical significance","volume":"79","author":"Selva-O\u2019Callaghan","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103206_bb0585","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1538-7836.2007.02669.x","article-title":"Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases","volume":"5","author":"Swadzba","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103206_bb0590","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.autrev.2022.103206_bb0595","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1021\/ac403194t","article-title":"Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology","volume":"85","author":"Martinez-Flores","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.autrev.2022.103206_bb0600","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13054-020-03066-3","article-title":"Beta-2-glycoprotein I as a biomarker for sepsis in critically ill patients in the intensive care unit: a prospective cohort study","volume":"24","author":"Schrijver","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2022.103206_bb0605","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11596-018-1889-y","article-title":"Thrombophilia caused by Beta2-Glycoprotein I deficiency: in vitro study of a rare mutation in APOH gene","volume":"38","author":"Zhang","year":"2018","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.autrev.2022.103206_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094946","article-title":"Antigens and antibodies of the antiphospholipid syndrome as new allies in the pathogenesis of COVID-19 coagulopathy","volume":"23","author":"Serrano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103206_bb0615","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1182\/blood-2005-05-2048","article-title":"Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus","volume":"106","author":"Male","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103206_bb0620","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1073\/pnas.96.9.5164","article-title":"Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides","volume":"96","author":"Blank","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103206_bb0625","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.97.9.900","article-title":"Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome","volume":"97","author":"George","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2022.103206_bb0630","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/pro.4054","article-title":"Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation-mechanisms analyzed using hydrogen\/deuterium exchange","volume":"30","author":"Tang","year":"2021","journal-title":"Protein Sci"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:17Z","timestamp":1761600437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":126,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1568997222001768"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103206","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 and the antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103206"}}